Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Search

Top

Back to Contracts

Preclinical In Vivo Efficacy Testing

Active

Grant

Response Deadline02/11/2027, 05:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract involves performing preclinical in vivo efficacy testing for vaccine candidates on behalf of prime contractors for NIH/NIAID malaria vaccine projects. The scope of work includes administering vaccines to vertebrate animal models, monitoring immune responses, and conducting tissue analysis and euthanasia. To qualify, the provider must maintain an AAALAC-accredited vivarium with specialized housing for malaria-susceptible species and strictly adhere to AVMA Guidelines for the Euthanasia of Animals. The primary deliverables for this engagement are comprehensive animal study reports and preclinical efficacy data. This opportunity is associated with NAICS code 541714 and is managed under the National Institutes of Health within the Department of Health and Human Services. The response deadline for this requirement is February 11, 2027.

General Info

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

This scope was carved out of RFA-AI-28-024.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedOct 13

subcontract

Response DeadlineFeb 11

Submission deadline

Response Deadline

02/11/2027, 05:00:00 AM UTCin 4 months

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health

Office AddressN/A

ContactsNo contact information available

Full Description

Show more

Performs preclinical testing of vaccine candidates for prime contractors on NIH/NIAID preclinical malaria vaccine projects. Administers vaccine candidates to vertebrate animal models, monitors immune response, and performs euthanasia and tissue analysis. Requires an AAALAC-accredited vivarium and specialized housing for malaria-susceptible species. Must comply with AVMA Guidelines for the Euthanasia of Animals. Delivers preclinical efficacy data and animal study reports.

Similar Contracts

Same NAICS industry code

Preclinical & Translational Research SupportThis subcontract for Preclinical and Translational Research Support involves providing specialized laboratory services and preclinical testing to prime contractors working on Defense Health Agency lupus research projects. The scope of work focuses on supporting the transition from laboratory research to clinical application through the development of animal models, in-vitro and in-vivo modeling, and preclinical toxicity testing. The primary deliverables include validated models and comprehensive preclinical test results. The project is managed under the Department of Defense for the Defense Health Agency and is categorized under NAICS code 541714. Performance of the contract will take place in Frederick, Maryland. Interested parties should note the response deadline of November 16, 2026.

Defense Health Agency

POSTED

about 14 hours ago

DEADLINE

in about 1 month

Patient Quality of Life (QoL) Clinical StudiesThis subcontract focuses on conducting patient-centric clinical research for the Defense Health Agency to evaluate factors affecting the quality of life for lupus patients. The scope of work includes comprehensive clinical trial management, the design of patient surveys, psychosocial assessments, and detailed health outcomes research. The primary objective is to generate and deliver clinical study reports and outcome data to prime contractors. The project is categorized under NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the response deadline is November 16, 2026, following a posting date of October 14, 2026.

Defense Health Agency

POSTED

about 14 hours ago

DEADLINE

in about 1 month

Disease Mechanism & Intervention ResearchThis subcontract opportunity involves conducting specialized research into lupus disease mechanisms and analyzing patient responses to medical interventions to support prime contractors on Defense Health Agency projects. The scope of work focuses on translational research, pharmacological studies, and the mapping of disease pathways to deliver critical analysis of intervention response data. The project is associated with NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the solicitation was posted on October 14, 2026, with a response deadline set for November 16, 2026.

Defense Health Agency

POSTED

about 14 hours ago

DEADLINE

in about 1 month

Lupus Genetic & Biological Subset ResearchThe Lupus Genetic and Biological Subset Research subcontract involves providing specialized biological and genetic analysis to support prime contractors on Defense Health Agency research projects. The scope of work focuses on identifying and categorizing lupus patient subsets to enable targeted treatment through genomic sequencing, biomarker identification, biological assay development, and detailed patient cohort analysis. The primary deliverable for this effort is the provision of categorized biological and genetic data sets. This project is managed under the Department of Defense for the Defense Health Agency, with performance taking place in Frederick, Maryland. The opportunity was posted on October 14, 2026, with a response deadline of November 16, 2026. The work is classified under NAICS code 541714, reflecting its focus on research and development in the biotechnology field.

Defense Health Agency

POSTED

about 14 hours ago

DEADLINE

in about 1 month

RFI Lupus Research Program (LRP) Public

Solicitation # HT9427RFI2027LRP

The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information under solicitation number HT9427RFI2027LRP to gather feedback for the Lupus Research Program. This initiative aims to inform future focus areas and research funding opportunities for fiscal year 2027. The program is specifically seeking input from academia, industry, non-profit organizations, federal agencies, and the general public to identify critical gaps in the field and underfunded research areas. Strategic goals include improving the quality of life for patients, gaining insight into disease mechanisms and heterogeneity, and advancing the understanding of lupus patient subsets to optimize treatment. This action is strictly for information and planning purposes and does not constitute a formal solicitation, request for proposals, or request for quotations. Consequently, no contract will be awarded based on this announcement, and there are no established deliverables or periods of performance. Interested parties are requested to provide their feedback via Survey Monkey by November 16, 2026, at 4:00 PM EST. While previous appropriations from fiscal years 2017 through 2026 totaled 75 million dollars, funds for fiscal year 2027 have not yet been appropriated.

Defense Health Agency

POSTED

about 14 hours ago

DEADLINE

in about 1 month

Specialized Vaccine Formulation ServicesThis subcontract for Specialized Vaccine Formulation Services supports the National Institutes of Health and the Department of Health and Human Services in advancing preclinical malaria vaccine projects. The selected provider will develop and test improved formulations and combination vaccine strategies for prime contractors, utilizing laboratory-scale equipment, stability chambers, and analytical tools such as HPLC or Mass Spec. Key responsibilities include performing formulation screening, stability testing, and the creation of delivery systems while maintaining strict compliance with federal laboratory safety and biohazard regulations. The primary deliverables for this engagement are validated vaccine formulations and comprehensive stability reports. Interested parties should note that the response deadline is February 11, 2027, and the work falls under NAICS code 541714.

National Institutes Of Health

POSTED

DEADLINE

Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-024

The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications for RFA-AI-28-024 to support the research and preclinical development of highly efficacious malaria vaccines. The initiative focuses on utilizing structure-based immunogen design, improved formulations, and combination vaccines to create long-lasting protection that can serve as a model for other mosquito-borne diseases. This funding opportunity is structured as a phased award, consisting of an R61 exploratory phase for up to three years with annual direct costs up to 400,000 dollars, and an R33 development phase for up to two years with annual direct costs up to 750,000 dollars. The maximum total project period is five years, and clinical trials are strictly prohibited. Applications will be evaluated through the NIH peer review system based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Key requirements include the establishment of quantifiable R61 transition milestones and clear translational Go/No-go criteria for vaccine candidates. Applicants must maintain active SAM registration and provide a Data Management and Sharing Plan. Additionally, recipients must adhere to strict cybersecurity protocols modeled after the NIST framework, including multifactor authentication and a 48-hour incident notification requirement, and ensure all research involving human subjects or vertebrate animals complies with federal regulations and ethical guidelines.

National Institutes Of Health

POSTED

DEADLINE

High-Throughput Functional Genomic AssayingThis subcontract, titled High-Throughput Functional Genomic Assaying, supports National Institutes of Health and NHGRI research projects by providing experimental testing of genomic variants. The scope of work involves implementing high-throughput assays to perturb variants and executing functional interpretation strategies utilizing CRISPR-based systems and high-throughput screening platforms. The selected provider is responsible for delivering raw molecular and cellular data along with all associated metadata. The project is managed under the Department of Health and Human Services and requires strict adherence to 45 CFR Part 46 regulations regarding human subjects research. The opportunity was posted on October 9, 2026, with a response deadline of December 14, 2026. It is categorized under NAICS code 541714 for research and development in biotechnology.

National Institutes Of Health

POSTED

DEADLINE

Specialized Phenotypic Assay Development/ExecutionThis subcontract, titled Specialized Phenotypic Assay Development/Execution, supports prime contractors on NIH IGVF Consortium projects under the Department of Health and Human Services. The primary objective is the collection of robust phenotypic data through the execution of imaging, proteomics, and transcriptomics assays designed to measure the impacts of variant interactions. To achieve this, the contractor will utilize advanced technical equipment, including mass spectrometers, flow cytometers, and high-content imaging systems. The scope of work emphasizes the delivery of high-quality phenotypic data sets while adhering to strict quality control standards for high-throughput data. This opportunity falls under NAICS code 541714 and was posted on October 9, 2026, with a response deadline of December 14, 2026.

National Institutes Of Health

POSTED

DEADLINE

Senescence-Specific Reagent and Tool ManufacturingThis subcontract, titled Senescence-Specific Reagent and Tool Manufacturing, supports National Institutes of Health projects focused on senescence technologies. The selected provider will develop and supply innovative reagents, biospecimens, and tools for prime contractors, specifically focusing on the creation of markers for phenotypic identifiers and the manufacture of reagents to identify senescence heterogeneity within secretomes and tissue environments. The scope of work requires the use of biotechnology laboratory facilities for antibody production and protein synthesis, with a final delivery of validated assays and physical reagents. All operations must strictly adhere to NIH guidelines regarding human systems. The opportunity was posted on October 9, 2026, with a response deadline of November 23, 2026, falling under NAICS code 541714.

National Institutes Of Health

POSTED

DEADLINE

in about 1 month

Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)

Solicitation # RFA-RM-27-007

The National Institutes of Health, under the Department of Health and Human Services, is soliciting the development or adaptation of innovative senescence technologies (SenTecs) through solicitation RFA-RM-27-007. These technologies aim to identify, characterize, and understand senescent cell heterogeneity within tissue environments and secretomes to improve strategies for modulating these cells in human aging and disease. The program utilizes a five-year, milestone-driven award structure divided into two phases: a two-year UG3 phase focused on development and feasibility, and a three-year UH3 phase dedicated to optimization, refinement, and validation. Transition to the UH3 phase is not automatic and requires an administrative review at the end of year two. The final year of the award requires a collaborative demonstration project within the SenNet consortium. The NIH intends to commit 5.4 million dollars in total costs for fiscal year 2027 to fund up to nine awards, with direct cost caps of 400,000 dollars per year for the UG3 phase and 550,000 dollars per year for the UH3 phase. Applications are evaluated based on the importance of the research, scientific rigor, feasibility, and the expertise of the investigators. Required submissions include an Intellectual Property Strategy and a Data Management and Sharing Plan. Awardees must adhere to strict cybersecurity incident reporting, maintain a seven-year confidentiality agreement for non-public information, and ensure all technical assets and data are deposited into the SenNet Data Portal. Clinical trials are not allowed under this specific opportunity.

National Institutes Of Health

POSTED

DEADLINE

in about 1 month

IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)

Solicitation # RFA-HG-27-008

The National Human Genome Research Institute (NHGRI), under the Department of Health and Human Services, is soliciting applications for the Impact of Genomic Variation on Function (IGVF) Data and Coordinating Center (DACC) via solicitation RFA-HG-27-008. The DACC will serve as the central hub for the IGVF Consortium, tasked with developing a comprehensive, searchable catalog of genomic function and variant impacts and managing a data portal for housing and sharing consortium resources. Key technical objectives include the hardening of data processing pipelines to ensure they are containerized, robust, and reproducible, while adopting existing data and metadata standards to promote interoperability. The NHGRI intends to commit 6 million dollars in total costs for the period of FY 2027-2031, with annual application budgets limited to 4 million dollars in direct costs. Funding decisions are based on scientific peer review and program-specific considerations, focusing on technical merit, synergy with other IGVF projects, and the applicant's capability to coordinate large-scale genomic data efforts. Applicants must maintain active registrations in SAM, eRA Commons, and Grants.gov, and all Principal Investigators must have a linked ORCID ID. Special requirements include a dedicated Project Manager devoting at least 6 person months and strict adherence to the Cybersecurity Act of 2015, which mandates reporting cybersecurity incidents within 48 hours of discovery. Proposals must include a Research Strategy limited to 30 pages and be submitted via an institutional system-to-system solution by the December 14, 2026, deadline.

National Institutes Of Health

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS